Egetis Therapeutics AB (publ) (STO:EGTX)

Egetis Therapeutics AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	378.4	215.8	351	303.3	127.7	144
Cash & Short-Term Investments	378.4	215.8	351	303.3	127.7	144
Cash Growth	86.77%	-38.52%	15.73%	137.51%	-11.32%	-49.97%
Accounts Receivable	3.7	19.2	15.5	28.2	3.8	3.5
Other Receivables	7.3	8.7	8.1	8.4	6.7	3.3
Receivables	11	27.9	23.6	36.6	10.5	6.8
Inventory	1.4	2.3	1	0.7	0.6	0.7
Prepaid Expenses	5.9	4.3	4.1	4.4	8.2	1.3
Other Current Assets	-	3.3	0.4	0.9	0.4	0.1
Total Current Assets	396.7	253.6	380.1	345.9	147.4	152.9
Property, Plant & Equipment	9	9.7	2.6	4.4	2.7	4.3
Long-Term Investments	0.8	0.8	0.8	0.8	0.8	0.8
Other Intangible Assets	1.6	2.2	3.2	4.3	5.4	6.5
Long-Term Deferred Tax Assets	1.5	1.7	0.6	-	-	-
Long-Term Deferred Charges	350.8	371.1	404.8	404.8	404.8	404.8
Other Long-Term Assets	0.1	-	0.2	-	-	-
Total Assets	760.5	639.1	792.3	760.2	561.1	569.3

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	16.5	21.8	25.7	28.7	20	4.6
Accrued Expenses	174.8	170.7	131	47.2	12.7	5.3
Current Portion of Long-Term Debt	64.7	31.5	30.1	5.2	-	-
Current Portion of Leases	-	2.9	2.5	2.2	1.6	1.5
Current Income Taxes Payable	-	0.1	0.2	0.1	-	-
Other Current Liabilities	10.7	13.9	14.7	20.5	15.1	27.8
Total Current Liabilities	266.7	240.9	204.2	103.9	49.4	39.2
Long-Term Debt	-	45	84.1	103.4	-	-
Long-Term Leases	4.1	5.6	0.4	2.2	1.1	2.7
Long-Term Deferred Tax Liabilities	1.4	1.7	0.5	-	-	-
Other Long-Term Liabilities	6.8	7.2	10.2	5.1	4.4	0.4
Total Liabilities	279	300.4	299.4	214.6	54.9	42.3

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	25.8	22.3	20.4	15.4	11.3	8.7
Additional Paid-In Capital	2,568	2,228	2,058	1,780	1,428	1,263
Retained Earnings	-2,152	-1,948	-1,610	-1,267	-939.6	-745.8
Comprehensive Income & Other	39.6	36.9	24.9	16.7	6.1	1.3
Shareholders' Equity	481.5	338.7	492.9	545.6	506.2	527
Total Liabilities & Equity	760.5	639.1	792.3	760.2	561.1	569.3

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	68.8	85	117.1	113	2.7	4.2
Net Cash (Debt)	309.6	130.8	233.9	190.3	125	139.8
Net Cash Growth	192.63%	-44.08%	22.91%	52.24%	-10.59%	-50.63%
Net Cash Per Share	0.77	0.35	0.75	0.73	0.64	0.78
Filing Date Shares Outstanding	464.95	395.16	359.24	292.57	214.59	165.07
Total Common Shares Outstanding	464.95	395.16	359.24	292.57	214.59	165.07
Working Capital	130	12.7	175.9	242	98	113.7
Book Value Per Share	1.04	0.86	1.37	1.86	2.36	3.19
Tangible Book Value	479.9	336.5	489.7	541.3	500.8	520.5
Tangible Book Value Per Share	1.03	0.85	1.36	1.85	2.33	3.15
Machinery	-	1.6	0.1	0.3	0.2	0.3

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 1, 2026

Data Sources Report a data error